AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9385303 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized display of charges for radiological tests
Number of subjects: 12271
Study 9385303 — intervention group
Group type: COMPARATOR
Intervention: Historical controls for clinical laboratory tests
Number of subjects: 12271
Study 7881586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hémovigilance system
Number of subjects: 0
Study 7881586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort studies on post‐transfusion hepatitis
Number of subjects: 0
Study 7881586 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized study on cytomegalovirus infections
Number of subjects: 0
Study 7881586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hémovigilance in the context of epidemics and new hazards
Number of subjects: 0
Study 3291533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum aspiration under general anesthesia
Number of subjects: 32
Study 3291533 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin (16,16 dimethyltrans‐delta 2PGE1 methyl ester in pessary form)
Number of subjects: 32
Study 30924381 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 12 months
Number of subjects: 144
Study 30924381 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy (control group)
Number of subjects: 144
Study 29878225 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 2862
Study 29878225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 2862
Study 29878225 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab→Lapatinib
Number of subjects: 2862
Study 29878225 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Lapatinib
Number of subjects: 2862
Study 29878225 — intervention group
Group type: COMPARATOR
Intervention: No TRA
Number of subjects: 2862
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus detection in conjunctival samples
Number of subjects: 62
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus 70 detection in conjunctival samples
Number of subjects: 62
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus 71 detection in conjunctival samples
Number of subjects: 62
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxsackievirus A16 detection in conjunctival samples
Number of subjects: 62
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxsackievirus A24 detection in conjunctival samples
Number of subjects: 62
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus detection in pharyngeal samples
Number of subjects: 62
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus 70 detection in pharyngeal samples
Number of subjects: 62
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus 71 detection in pharyngeal samples
Number of subjects: 62
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxsackievirus A16 detection in pharyngeal samples
Number of subjects: 62
Study 28535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxsackievirus A24 detection in pharyngeal samples
Number of subjects: 62
Study 26208378 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment
Number of subjects: 236
Study 26208378 — intervention group
Group type: COMPARATOR
Intervention: No aspirin pretreatment
Number of subjects: 236
Study 23756308 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational videotaped message (autonomy-supportive)
Number of subjects: 415
Study 23756308 — intervention group
Group type: COMPARATOR
Intervention: Brochure (neutral message)
Number of subjects: 415
Study 21354028 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 19
Study 21354028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19881436 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based (CB) questions
Number of subjects: 130
Study 19881436 — intervention group
Group type: COMPARATOR
Intervention: Non-case-based (non-CB) questions
Number of subjects: 130
Study 19881436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest
Number of subjects: 130
Study 17542110 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement containing vitamin A, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, calcium pantothenate, vitamin C, vitamin E, iron, lysine, and calcium, daily for 9 months
Number of subjects: 413
Study 17542110 — intervention group
Group type: COMPARATOR
Intervention: Control group with no nutritional intervention
Number of subjects: 413
Study 12594004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 50 mg denaverine hydrochloride
Number of subjects: 0
Study 12594004 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 50 mg denaverine hydrochloride in aqueous solution
Number of subjects: 0
Study 12594004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of 50 mg denaverine hydrochloride in aqueous solution
Number of subjects: 0
Study 12594004 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository formulation of 50 mg denaverine hydrochloride
Number of subjects: 0
Study 10632281 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioners
Number of subjects: 1316
Study 10632281 — intervention group
Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 1316
Study 9360031 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (30 min, 3-4 times weekly for 6 weeks)
Number of subjects: 41
Study 9360031 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation program)
Number of subjects: 41
Study 1551298 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine hydrochloride 25 mg p.o. four times a day (total, 10 doses)
Number of subjects: 20
Study 1551298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3838406 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg of SIN-1
Number of subjects: 23
Study 3838406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30861550 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dose apixaban
Number of subjects: 500
Study 30861550 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation (standard of care)
Number of subjects: 500
Study 30202851 — intervention group
Group type: EXPERIMENTAL
Intervention: DZX + placebo (DZX + PL)
Number of subjects: 12
Study 30202851 — intervention group
Group type: EXPERIMENTAL
Intervention: DZX + metformin (DZX + MTF)
Number of subjects: 12
Study 30202851 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (PL + PL)
Number of subjects: 12
Study 30202851 — intervention group
Group type: EXPERIMENTAL
Intervention: DZX treatment
Number of subjects: 12
Study 27377085 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 81
Study 27377085 — intervention group
Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 81
Study 24811940 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume ≤6 ml/kg PBW
Number of subjects: 2184
Study 24811940 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume ≥10 ml/kg PBW
Number of subjects: 2184
Study 24811940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation needs (propofol and midazolam)
Number of subjects: 2184
Study 20670085 — intervention group
Group type: EXPERIMENTAL
Intervention: FDR gemcitabine (1,000 mg/m² on days 1 and 15), oxaliplatin (60 mg/m² on days 1 and 15), capecitabine (1,000 mg/m² BID on days 1-7 and 15-21)
Number of subjects: 77
Study 20670085 — intervention group
Group type: EXPERIMENTAL
Intervention: FDR gemcitabine, oxaliplatin, and capecitabine regimen
Number of subjects: 77
Study 19440076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administered by cigarette smoking
Number of subjects: 40
Study 19440076 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of nicotine gum
Number of subjects: 40
Study 19440076 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 40
Study 19440076 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 40
Study 17342790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender inhalation
Number of subjects: 70
Study 17342790 — intervention group
Group type: COMPARATOR
Intervention: Sunflower inhalation
Number of subjects: 70
Study 15041620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 40 mg (Group T(40))
Number of subjects: 100
Study 15041620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg (Group T(100))
Number of subjects: 100
Study 15041620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg (Group T(200))
Number of subjects: 100
Study 15041620 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride (Group P)
Number of subjects: 100
Study 11352774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant (10 mg) administered intravenously over 5 min
Number of subjects: 71
Study 11352774 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously over 5 min
Number of subjects: 71
Study 9223077 — intervention group
Group type: EXPERIMENTAL
Intervention: Global motion coherence thresholds test
Number of subjects: 0
Study 9223077 — intervention group
Group type: COMPARATOR
Intervention: Visuo-manual accuracy in posting a card through a slot
Number of subjects: 0
Study 8491237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 250 mg b.d.
Number of subjects: 48
Study 8491237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 500 mg b.d.
Number of subjects: 48
Study 8491237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2955964 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 48
Study 2955964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 607511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic somatostatin
Number of subjects: 0
Study 607511 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 0
Study 607511 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 31812327 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session intervention alongside treatment-as-usual (TAU)
Number of subjects: 34
Study 31812327 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)-only
Number of subjects: 34
Study 30616601 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT scan prior to SRT planning (n = 103)
Number of subjects: 193
Study 30616601 — intervention group
Group type: COMPARATOR
Intervention: Standard SRT (control arm 1, n = 90)
Number of subjects: 193
Study 28960818 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone interbody spacer at C4–C5 and C5–C6
Number of subjects: 11
Study 28960818 — intervention group
Group type: COMPARATOR
Intervention: Two-level locking static plate
Number of subjects: 11
Study 28960818 — intervention group
Group type: COMPARATOR
Intervention: Rotational-dynamic plate
Number of subjects: 11
Study 28960818 — intervention group
Group type: COMPARATOR
Intervention: Comparison of two plating systems (locking static plate vs rotational-dynamic plate)
Number of subjects: 11
Study 26013300 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin transfusion threshold of 70 g/L
Number of subjects: 0
Study 26013300 — intervention group
Group type: COMPARATOR
Intervention: Hemoglobin transfusion threshold of 90 g/L
Number of subjects: 0
Study 23374004 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm isotope monotherapy
Number of subjects: 177
Study 23374004 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (153Sm + EBRT)
Number of subjects: 177
Study 21060997 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-quit reaction times on a computerized modified Simon task (10-h nicotine-deprived vs. not deprived)
Number of subjects: 365
Study 21060997 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing positive and smoking slides
Number of subjects: 365
Study 21060997 — intervention group
Group type: COMPARATOR
Intervention: Viewing negative slides
Number of subjects: 365
Study 19873913 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye acupuncture combined with oral administration of compound Danshen tablets
Number of subjects: 60
Study 19873913 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of compound Danshen tablets
Number of subjects: 60
Study 16835737 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids/local anaesthetics
Number of subjects: 40
Study 16835737 — intervention group
Group type: COMPARATOR
Intervention: Saline/local anaesthetic
Number of subjects: 40
Study 15213584 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate plus psychosocial treatment (parent training, counseling, social skills training, academic assistance, psychotherapy)
Number of subjects: 103
Study 15213584 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate alone
Number of subjects: 103
Study 15213584 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate plus attention control treatment
Number of subjects: 103
Study 15213584 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including methylphenidate alone and with psychosocial treatment)
Number of subjects: 103
Study 11555194 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN + Zn (Interferon with polaprezinc)
Number of subjects: 75
Study 11555194 — intervention group
Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 75
Study 11555194 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN + Zn
Number of subjects: 75
Study 10209404 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held Doppler (HHD) assessment
Number of subjects: 72
Study 10209404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet testing
Number of subjects: 72
Study 10209404 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective duplex scanning
Number of subjects: 72
Study 10209404 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective criteria for duplex scanning
Number of subjects: 72
Study 7949546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical ureteroneocystostomy (LP)
Number of subjects: 0
Study 7949546 — intervention group
Group type: COMPARATOR
Intervention: Extravesical ureteroneocystostomy (Lich)
Number of subjects: 0
Study 3239469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Cigarettes
Number of subjects: 0
Study 3239469 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Free Cigarettes
Number of subjects: 0
Study 3239469 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprived
Number of subjects: 0
Study 3239469 — intervention group
Group type: COMPARATOR
Intervention: Nondeprived
Number of subjects: 0
Study 31899383 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Nursing Practice Guideline (CNPG) of Enteral Nutrition (EN) care
Number of subjects: 44
Study 31899383 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 44
Study 30211929 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial injection of autologous bone marrow-derived CD133+ stem cells
Number of subjects: 31
Study 30211929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 28183323 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT intervention with home monitoring kit including home-leaving sensors, smoke and water leak sensors, bed sensors, and automatic lights
Number of subjects: 320
Study 28183323 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study 25594550 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) levels above the upper limit of normal (65 pg/mL)
Number of subjects: 1840
Study 25594550 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH levels (per 10 units increase)
Number of subjects: 1840
Study 25594550 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH levels
Number of subjects: 1840
Study 24244450 — intervention group
Group type: EXPERIMENTAL
Intervention: Keypress turning words ON
Number of subjects: 0
Study 24244450 — intervention group
Group type: EXPERIMENTAL
Intervention: Keypress turning words OFF
Number of subjects: 0
Study 24244450 — intervention group
Group type: EXPERIMENTAL
Intervention: Keypress with aversive tone ON/OFF
Number of subjects: 0
Study 24244450 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable association between responses and effects
Number of subjects: 0
Study 24244450 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective response effects assessing implicit in-group favoritism
Number of subjects: 0
Study 20838324 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM regimen (5‐fluorouracil 600 mg/m(2) IV drip on days 1, 8, 29, and 36; doxorubicin 30 mg/m(2) IV bolus injection on days 1 and 29; mitomycin‐C 10 mg/m(2) IV bolus injection on day 1; repeated every 8 weeks)
Number of subjects: 268
Study 20838324 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen (oxaliplatin 100 mg/m(2) IV drip on days 1 and 15; leucovorin 400 mg/m(2) IV drip on days 1 and 15; 5‐FU 400 mg/m(2) IV bolus injection; 5‐FU 2.4/3.0 mg/m(2) continuous IV infusion for 48 hours on day 1, 2, 15, and 16; repeated every 4 weeks for at least 4 cycles)
Number of subjects: 268
Study 20838324 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy (FAM and FOLFOX regimens combined)
Number of subjects: 268
Study 18307374 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (twice-daily dosing)
Number of subjects: 1009
Study 17075373 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ppm inhaled nitric oxide
Number of subjects: 385
Study 17075373 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 385
Study 15514886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioglass used in group B (14 cases)
Number of subjects: 39
Study 15514886 — intervention group
Group type: COMPARATOR
Intervention: Autogenous iliac cancellous bone in group A (25 cases)
Number of subjects: 39
Study 15514886 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 39
Study 15514886 — intervention group
Group type: COMPARATOR
Intervention: Comparison between complete and incomplete alveolar cleft in both groups
Number of subjects: 39
Study 11346212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cystic artery TAE (Group 1, 20 patients)
Number of subjects: 40
Study 11346212 — intervention group
Group type: COMPARATOR
Intervention: Post-cystic artery TAE (Group 2, 20 patients)
Number of subjects: 40
Study 9237711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pn‐CRM197 vaccines (5 microg)
Number of subjects: 400
Study 9237711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pn‐CRM197 vaccines (2 microg)
Number of subjects: 400
Study 9237711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pn‐CRM197 vaccines (0.5 microg)
Number of subjects: 400
Study 9237711 — intervention group
Group type: EXPERIMENTAL
Intervention: PS formulations
Number of subjects: 400
Study 9237711 — intervention group
Group type: EXPERIMENTAL
Intervention: PS vaccines (5 microg)
Number of subjects: 400
Study 9237711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pn‐CRM197 vaccines
Number of subjects: 400
Study 9237711 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine with Pn‐CRM197
Number of subjects: 400
Study 9237711 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 400
Study 8218691 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium mupirocin ointment (n = 170)
Number of subjects: 339
Study 8218691 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment (n = 169)
Number of subjects: 339
Study 3550021 — intervention group
Group type: COMPARATOR
Intervention: PRP vaccine
Number of subjects: 585
Study 3550021 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 585
Study 29292114 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac vein stenting
Number of subjects: 58
Study 29292114 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 58
Study 27855100 — intervention group
Group type: EXPERIMENTAL
Intervention: Online 'LARC First' training and rapid referral pathways
Number of subjects: 729
Study 27855100 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 729
Study 24323641 — intervention group
Group type: EXPERIMENTAL
Intervention: safinamide 100 mg/day
Number of subjects: 669
Study 24323641 — intervention group
Group type: EXPERIMENTAL
Intervention: safinamide 50 mg/day
Number of subjects: 669
Study 24323641 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 669
Study 23466078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 795
Study 23466078 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 795
Study 20589977 — intervention group
Group type: COMPARATOR
Intervention: Continued absence of LVH
Number of subjects: 663
Study 20589977 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of LVH
Number of subjects: 663
Study 20589977 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent LVH
Number of subjects: 663
Study 20589977 — intervention group
Group type: EXPERIMENTAL
Intervention: New ECG LVH
Number of subjects: 663
Study 20589977 — intervention group
Group type: EXPERIMENTAL
Intervention: New LVH
Number of subjects: 663
Study 18004283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 28
Study 18004283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16677528 — intervention group
Group type: EXPERIMENTAL
Intervention: itraconazole 200 mg Bid
Number of subjects: 21
Study 16677528 — intervention group
Group type: EXPERIMENTAL
Intervention: itraconazole 200 mg qd
Number of subjects: 21
Study 12882842 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 70/30 mix plus metformin
Number of subjects: 188
Study 12882842 — intervention group
Group type: COMPARATOR
Intervention: Triple oral therapy
Number of subjects: 188
Study 10827161 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interferon‐alfa (6 MU subcutaneously 3 times weekly for 6 months followed by 3 MU for 6 months) and ribavirin (for 4, 6, or 12 months) in group C (n=129)
Number of subjects: 307